Predicting 1p/19q co-deletion status from magnetic resonance imaging using deep learning in adult-type diffuse lower-grade gliomas: a discovery and validation study.

Journal: Laboratory investigation; a journal of technical methods and pathology
PMID:

Abstract

Determination of 1p/19q co-deletion status is important for the classification, prognostication, and personalized therapy in diffuse lower-grade gliomas (LGG). We developed and validated a deep learning imaging signature (DLIS) from preoperative magnetic resonance imaging (MRI) for predicting the 1p/19q status in patients with LGG. The DLIS was constructed on a training dataset (n = 330) and validated on both an internal validation dataset (n = 123) and a public TCIA dataset (n = 102). The receiver operating characteristic (ROC) analysis and precision recall curves (PRC) were used to measure the classification performance. The area under ROC curves (AUC) of the DLIS was 0.999 for training dataset, 0.986 for validation dataset, and 0.983 for testing dataset. The F1-score of the prediction model was 0.992 for training dataset, 0.940 for validation dataset, and 0.925 for testing dataset. Our data suggests that DLIS could be used to predict the 1p/19q status from preoperative imaging in patients with LGG. The imaging-based deep learning has the potential to be a noninvasive tool predictive of molecular markers in adult diffuse gliomas.

Authors

  • Jing Yan
    Department of Neurology, Shanghai Pudong New Area People's Hospital, Shanghai, China.
  • Shenghai Zhang
    Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • Qiuchang Sun
    Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • Weiwei Wang
  • Wenchao Duan
    Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Li Wang
    College of Marine Electrical Engineering, Dalian Maritime University, Dalian, China.
  • Tianqing Ding
    Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • Dongling Pei
    Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Chen Sun
    State Key Laboratory of Characteristic Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Wenqing Wang
    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.
  • Zhen Liu
    School of Pharmacy, Fudan University, PR China; Analytical Service Unit, WuXi AppTec (Shanghai) Co., Ltd, Shanghai, 200131, PR China.
  • Xuanke Hong
    Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Xiangxiang Wang
    School of Information and Software Engineering, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China.
  • Yu Guo
    Animal Disease Control Center of Inner Mongolia, Hohhot, China.
  • Wencai Li
    The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, PR China.
  • Jingliang Cheng
    Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Xianzhi Liu
    Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhi-Cheng Li
    Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. zc.li@siat.ac.cn.
  • Zhenyu Zhang
    Laboratory of Industrial Biotechnology of Department of Education, Jiangnan University, Wuxi 214122, Jiangsu, China.